{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:02:23Z","timestamp":1787029343763,"version":"build-2736575974"},"reference-count":112,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial therapeutic development, providing fast and reversible suppression of gonadotropins by directly blocking GnRH-R. Unlike typical GnRH agonists, these antagonists prevent the early hormonal flare, have a faster onset of action, and have a lower risk of cardiovascular problems. These characteristics qualify GnRH antagonists as revolutionary therapy for diseases such as advanced prostate cancer, endometriosis, uterine fibroids, and in vitro fertilization procedures. Key GnRH peptide antagonists authorized by the regulatory agencies include Cetrorelix, Ganirelix, Abarelix, Degarelix, and Teverelix. Assisted reproductive technologies (ART) are dominated by Cetrorelix and Ganirelix, while Degarelix and Abarelix have shown significant promise in treating advanced prostate cancer. Teverelix appears as a next-generation GnRH antagonist with an ideal mix of efficacy and safety, showing promise in a variety of reproductive and hormone-dependent illnesses. This review investigates the pharmacological role of GnRH in reproductive physiology and its consequences in disease, emphasizing structural advances in third- and fourth-generation GnRH antagonists. All GnRH peptide-based antagonists were analyzed in detail for formulation strategy, pharmacokinetics, effectiveness, and safety. This review also emphasizes GnRH antagonists\u2019 clinical promise, providing insights into their evolution and the possibility for future research in developing safer, more effective treatments for complicated hormonal diseases.<\/jats:p>","DOI":"10.3390\/ph18010036","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T13:26:25Z","timestamp":1735651585000},"page":"36","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8474-2463","authenticated-orcid":false,"given":"Shikha","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma University, Ahmedabad 382481, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8346-5679","authenticated-orcid":false,"given":"Bhagawati","family":"Saxena","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad 382481, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-2145","authenticated-orcid":false,"given":"Priti","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma University, Ahmedabad 382481, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-0336","authenticated-orcid":false,"given":"Sarfaraz K.","family":"Niazi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wu, H.-M., Chang, H.-M., and Leung, P.C.K. (2021). Gonadotropin-Releasing Hormone Analogs: Mechanisms of Action and Clinical Applications in Female Reproduction. Front. Neuroendocrinol., 60.","DOI":"10.1016\/j.yfrne.2020.100876"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.173.4001.1036","article-title":"Gonadotropin-Releasing Hormone: One Polypeptide Regulates Secretion of Luteinizing and Follicle-Stimulating Hormones","volume":"173","author":"Schally","year":"1971","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0006-291X(71)90766-2","article-title":"Isolation and Properties of the FSH and LH-Releasing Hormone","volume":"43","author":"Schally","year":"1971","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1073\/pnas.69.1.278","article-title":"Primary Structure of the Ovine Hypothalamic Luteinizing Hormone-Releasing Factor (LRF)","volume":"69","author":"Burgus","year":"1972","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.anireprosci.2005.05.005","article-title":"GnRH Analogues\u2014Agonists and Antagonists","volume":"88","author":"Padula","year":"2005","journal-title":"Anim. Reprod. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Depalo, R., Jayakrishan, K., Garruti, G., Totaro, I., Panzarino, M., Giorgino, F., and Selvaggi, L.E. (2012). GnRH Agonist versus GnRH Antagonist in in Vitro Fertilization and Embryo Transfer (IVF\/ET). Reprod. Biol. Endocrinol., 10.","DOI":"10.1186\/1477-7827-10-26"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/aja.aja_22_20","article-title":"Androgen Deprivation Therapy and Side Effects: Are GnRH Antagonists Safer?","volume":"23","author":"Freedland","year":"2021","journal-title":"Asian J. Androl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2022.2033210","article-title":"Advances with Androgen Deprivation Therapy for Prostate Cancer","volume":"23","author":"Yu","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_9","unstructured":"(2012). Bethesda (MD) Gonadotropin Releasing Hormone (GnRH) Analogues, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dwyer, A.A., and Quinton, R. (2019). Anatomy and Physiology of the Hypothalamic-Pituitary-Gonadal (HPG) Axis. Advanced Practice in Endocrinology Nursing, Springer International Publishing.","DOI":"10.1007\/978-3-319-99817-6_43"},{"key":"ref_11","unstructured":"Feingold, K., Anawalt, B., and Blackman, M. (2000). Physiology of GnRH and Gonadotropin Secretion. Endotext, MDText.com, Inc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.metabol.2017.11.018","article-title":"The Hypothalamus-Pituitary-Gonad Axis: Tales of Mice and Men","volume":"86","author":"Kaprara","year":"2018","journal-title":"Metabolism"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105230","DOI":"10.1016\/j.yhbeh.2022.105230","article-title":"The Roles of GnRH in the Human Central Nervous System","volume":"145","author":"Wickramasuriya","year":"2022","journal-title":"Horm. Behav."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Casati, L., Ciceri, S., Maggi, R., and Bottai, D. (2023). Physiological and Pharmacological Overview of the Gonadotropin Releasing Hormone. Biochem. Pharmacol., 212.","DOI":"10.1016\/j.bcp.2023.115553"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"GUILLEMIN, R. (1977). The Expanding Significance of Hypothalamic Peptides, or, Is Endocrinology a Branch of Neuroendocrinology?. Proceedings of the 1976 Laurentian Hormone Conference, Elsevier.","DOI":"10.1016\/B978-0-12-571133-3.50008-8"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sperduti, S., Limoncella, S., Lazzaretti, C., Paradiso, E., Riccetti, L., Turchi, S., Ferrigno, I., Bertacchini, J., Palumbo, C., and Pot\u00ec, F. (2019). GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225548"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/humupd\/dmv059","article-title":"GnRH and GnRH Receptors in the Pathophysiology of the Human Female Reproductive System","volume":"22","author":"Maggi","year":"2016","journal-title":"Hum. Reprod. Update"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Flanagan, C.A., and Manilall, A. (2017). Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00274"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1210\/me.2012-1045","article-title":"GnRH Regulation of Jun and Atf3 Requires Calcium, Calcineurin, and NFAT","volume":"26","author":"Binder","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2042018818772775","article-title":"The Role of Mitogen-Activated Protein Kinase-Extracellular Receptor Kinase Pathway in Female Fertility Outcomes: A Focus on Pituitary Gonadotropins Regulation","volume":"9","author":"Kahnamouyi","year":"2018","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S0006-291X(71)80019-0","article-title":"Structure of the Porcine LH- and FSH-Releasing Hormone. I. The Proposed Amino Acid Sequence","volume":"43","author":"Matsuo","year":"1971","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1210\/en.2008-0184","article-title":"Origins of Gonadotropin-Releasing Hormone (GnRH) in Vertebrates: Identification of a Novel GnRH in a Basal Vertebrate, the Sea Lamprey","volume":"149","author":"Kavanaugh","year":"2008","journal-title":"Endocrinology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Desaulniers, A.T., Cederberg, R.A., Lents, C.A., and White, B.R. (2017). Expression and Role of Gonadotropin-Releasing Hormone 2 and Its Receptor in Mammals. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00269"},{"key":"ref_24","first-page":"e38136","article-title":"Gonadotropin-Releasing Hormone (GnRH)\/GnRH Receptors and Their Role in the Treatment of Endometriosis","volume":"15","author":"Resta","year":"2023","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Whitlock, K.E., Postlethwait, J., and Ewer, J. (2019). Neuroendocrinology of Reproduction: Is Gonadotropin-Releasing Hormone (GnRH) Dispensable?. Front. Neuroendocrinol., 53.","DOI":"10.1016\/j.yfrne.2019.02.002"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Desaulniers, A.T., and White, B.R. (2024). Role of Gonadotropin-Releasing Hormone 2 and Its Receptor in Human Reproductive Cancers. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1341162"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.regpep.2006.05.004","article-title":"In Vivo Characterization of a Novel GnRH (Gonadotropin-Releasing Hormone) Antagonist, LXT-101, in Normal Male Rats","volume":"136","author":"Chi","year":"2006","journal-title":"Regul. Pept."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1210\/er.2003-0002","article-title":"Gonadotropin-Releasing Hormone Receptors","volume":"25","author":"Millar","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_29","first-page":"150","article-title":"Physiology of Gonadotropin-Releasing Hormone (Gnrh): Beyond the Control of Reproductive Functions","volume":"2","author":"Maggi","year":"2016","journal-title":"MOJ Anat. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gr\u00fcndker, C., and Emons, G. (2017). The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00187"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Emons, G., and Gr\u00fcndker, C. (2021). The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer. Cells, 10.","DOI":"10.3390\/cells10020292"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gr\u00fcndker, C., and Emons, G. (2021). Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer. Cells, 10.","DOI":"10.3390\/cells10020437"},{"key":"ref_33","first-page":"33","article-title":"Clinical Development of the GnRH Agonist Leuprolide Acetate Depot","volume":"4","author":"Chwalisz","year":"2023","journal-title":"F S Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/pros.23360","article-title":"Discovery of LHRH and Development of LHRH Analogs for Prostate Cancer Treatment","volume":"77","author":"Schally","year":"2017","journal-title":"Prostate"},{"key":"ref_35","first-page":"83","article-title":"Clinical Applications of Gonadotropin-Releasing Hormone Analogues: A Broad Impact on Reproductive Medicine","volume":"4","author":"Saleh","year":"2023","journal-title":"F S Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-014-1682-1","article-title":"Clinical Pharmacology and Regulatory Consequences of GnRH Analogues in Prostate Cancer","volume":"70","author":"Eckstein","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1472-6483(11)60210-1","article-title":"Gonadotrophin-Releasing Hormone (GnRH) and GnRH Agonists: Mechanisms of Action","volume":"5","author":"Ortmann","year":"2002","journal-title":"Reprod. Biomed. Online"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2016.10.034","article-title":"Temporary Ovarian Suppression during Chemotherapy to Preserve Ovarian Function and Fertility in Breast Cancer Patients: A GRADE Approach for Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology","volume":"71","author":"Lambertini","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient\u2013Level Data","volume":"36","author":"Lambertini","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update","volume":"36","author":"Oktay","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1093\/humrep\/deq240","article-title":"Cell Proliferation Effect of GnRH Agonist on Pathological Lesions of Women with Endometriosis, Adenomyosis and Uterine Myoma","volume":"25","author":"Khan","year":"2010","journal-title":"Hum. Reprod."},{"key":"ref_42","first-page":"CD012846","article-title":"GnRH Agonists for Uterine Fibroids","volume":"2017","author":"Hodgson","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_43","first-page":"40","article-title":"GnRH Agonists in the Treatment of Symptomatic Endometriosis: A Review","volume":"4","author":"Surrey","year":"2023","journal-title":"F S Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Popovic, J., Geffner, M.E., Rogol, A.D., Silverman, L.A., Kaplowitz, P.B., Mauras, N., Zeitler, P., Eugster, E.A., and Klein, K.O. (2022). Gonadotropin-Releasing Hormone Analog Therapies for Children with Central Precocious Puberty in the United States. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.968485"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1567201819666211224113311","article-title":"Preparation of Long-Acting Somatostatin and GnRH Analogues and Their Applications in Tumor Therapy","volume":"19","author":"Yu","year":"2022","journal-title":"Curr. Drug Deliv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.fertnstert.2008.09.077","article-title":"Aromatase Inhibitors Prevent the Estrogen Rise Associated with the Flare Effect of Gonadotropins in Patients Treated with GnRH Agonists","volume":"91","author":"Bedaiwy","year":"2009","journal-title":"Fertil. Steril."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bpobgyn.2006.08.002","article-title":"GnRH Agonists vs Antagonists","volume":"21","author":"Tarlatzis","year":"2007","journal-title":"Best. Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.fertnstert.2019.09.037","article-title":"Short- and Long-Term Impact of Gonadotropin-Releasing Hormone Analogue Treatment on Bone Loss and Fracture","volume":"112","author":"Alvero","year":"2019","journal-title":"Fertil. Steril."},{"key":"ref_49","first-page":"2787","article-title":"Bone Loss in Men with Prostate Cancer Treated with Gonadotropin-Releasing Hormone Agonists 1","volume":"86","author":"Stoch","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","article-title":"Differential Impact of Gonadotropin-Releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"79","author":"Abufaraj","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gu, L., Li, X., and Liu, W. (2023). Adverse Cardiovascular Effect Following Gonadotropin-Releasing Hormone Antagonist versus GnRH Agonist for Prostate Cancer Treatment: A Systematic Review and Meta-Analysis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1157857"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hruby, V.J., and Patel, D. (1995). Structure\u2013Function Studies of Peptide Hormones: An Overview. Peptides, Elsevier.","DOI":"10.1016\/B978-012310920-0\/50007-3"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Avenda\u00f1o, C., and Men\u00e9ndez, J.C. (2008). Anticancer Drugs That Inhibit Hormone Action. Medicinal Chemistry of Anticancer Drugs, Elsevier.","DOI":"10.1016\/B978-0-444-52824-7.00003-2"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Karten, M.J. (1992). An Overview of GnRH Antagonist Development: Two Decades of Progress. Modes of Action of GnRH and GnRH Analogs, Springer.","DOI":"10.1007\/978-1-4612-2916-2_18"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Nestor, J.J. (1987). Development of LHRH Antagonists. LHRH and Its Analogs, Springer.","DOI":"10.1007\/978-94-009-3229-6_1"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1210\/jcem-72-4-927","article-title":"Inhibition of Follicular Development by a Potent Antagonistic Analog of Gonadotropin-Releasing Hormone (Detirelix)","volume":"72","author":"Marshall","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0272-0590(91)90201-E","article-title":"Acute and Subchronic Toxicity Studies with Detirelix, a Luteinizing Hormone-Releasing Hormone Antagonist, in the Rat and Monkey","volume":"17","author":"Chester","year":"1991","journal-title":"Fundam. Appl. Toxicol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/j.1464-410X.2009.08924.x","article-title":"Abarelix and Other Gonadotrophin-releasing Hormone Antagonists in Prostate Cancer","volume":"104","author":"Kirby","year":"2009","journal-title":"BJU Int."},{"key":"ref_59","first-page":"S59","article-title":"Androgen Deprivation and Other Treatments for Advanced Prostate Cancer","volume":"3","author":"Brawer","year":"2001","journal-title":"Rev. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"175192","DOI":"10.1016\/j.ejphar.2022.175192","article-title":"In Vivo Degradation Forms, Anti-Degradation Strategies, and Clinical Applications of Therapeutic Peptides in Non-Infectious Chronic Diseases","volume":"932","author":"Tasdemiroglu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/CIA.S3503","article-title":"Degarelix and Its Therapeutic Potential in the Treatment of Prostate Cancer","volume":"4","author":"Doehn","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The Efficacy and Safety of Degarelix: A 12-month, Comparative, Randomized, Open-label, Parallel-group Phase III Study in Patients with Prostate Cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1442-2042.2012.02997.x","article-title":"Gonadotropin-releasing Hormone: An Update Review of the Antagonists versus Agonists","volume":"19","author":"Klotz","year":"2012","journal-title":"Int. J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/cpdd.1008","article-title":"Pharmacokinetic, Safety, and Pharmacodynamic Properties of Teverelix Trifluoroacetate, a Novel Gonadotropin-Releasing Hormone Antagonist, in Healthy Adult Subjects","volume":"11","author":"MacLean","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/pros.24674","article-title":"Efficacy, Tolerability, and Safety of Teverelix DP in Patients with Advanced Prostate Cancer: A Multicenter, Open-label, Phase 2 Trial","volume":"84","author":"Ulys","year":"2024","journal-title":"Prostate"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ulys, A., \u010cerniauskien\u0117, A., Geavlete, P., Larsen, F., MacLean, C.M., and van Os, S. (2024). Teverelix Is a Potential Treatment Option for the Prevention of Acute Urinary Retention Recurrence in Men Suffering from Benign Prostatic Hyperplasia. Int. Urol. Nephrol.","DOI":"10.1007\/s11255-024-04235-x"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"MacLean, C.M., Ulys, A., Jankevi\u010dius, F., Salad\u017einskas, \u017d., van Os, S., and Larsen, F. (2023). Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies. Medicina, 59.","DOI":"10.3390\/medicina59040681"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Baldo, B.A. (2016). Peptide Hormones. Safety of Biologics Therapy, Springer International Publishing.","DOI":"10.1007\/978-3-319-30472-4"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Szab\u00f3, Z., Dezs\u0151, B., Fodor, K., Szegedi, K., Flask\u00f3, T., Szab\u00f3, E., Ol\u00e1h, G., Sipos, \u00c9., Dobos, N., and Gardi, J. (2021). Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer. Molecules, 26.","DOI":"10.3390\/molecules26051253"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/humupd\/6.4.322","article-title":"The LHRH Antagonist Cetrorelix: A Review","volume":"6","author":"Reissmann","year":"2000","journal-title":"Hum. Reprod. Update"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/acs.molpharmaceut.1c00883","article-title":"Aggregation Behavior of Structurally Similar Therapeutic Peptides Investigated by 1 H NMR and All-Atom Molecular Dynamics Simulations","volume":"19","author":"Hjalte","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_72","unstructured":"ORGANON & Co. (2024). Ganirelix Acetate Injection, ORGANON & Co."},{"key":"ref_73","unstructured":"EMD Serono, Inc. (2024). Cetrotide\u00ae 0.25 Mg (Cetrorelix Acetate for Injection), EMD Serono, Inc."},{"key":"ref_74","first-page":"CD001750","article-title":"Gonadotrophin-Releasing Hormone Antagonists for Assisted Reproductive Technology","volume":"2016","author":"Youssef","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_75","unstructured":"Praecis Pharmaceuticals Incorporated (2003). Plenaxis (Abarelix Suspension for Injection)\u2014NDA 21-320, Praecis Pharmaceuticals Incorporated."},{"key":"ref_76","unstructured":"Ferring Pharmaceuticals Inc. (2008). Degarelix for Injection\u2014NDA 22201, Ferring Pharmaceuticals Inc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.301.1.95","article-title":"Pharmacological Profile of a New, Potent, and Long-Acting Gonadotropin-Releasing Hormone Antagonist: Degarelix","volume":"301","author":"Broqua","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_78","unstructured":"U.S. FDA (2003). Plenaxis TM RISK MANAGEMENT PROGRAM."},{"key":"ref_79","unstructured":"U.S. FDA (2024). Cetrotide \u00ae (Cetrorelix Acetate for Injection_Label."},{"key":"ref_80","unstructured":"U.S. FDA (2023). Ganirelix Acetate Injection."},{"key":"ref_81","unstructured":"U.S. FDA (2020). FIRMAGON\u00ae (Degarelix for Injection) for Subcutaneous Use."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Li, X., Wang, N., Liu, Y., Li, W., Bai, X., Liu, P., and He, C.-Y. (2023). Backbone N-Methylation of Peptides: Advances in Synthesis and Applications in Pharmaceutical Drug Development. Bioorg Chem., 141.","DOI":"10.1016\/j.bioorg.2023.106892"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1517\/13543770903410237","article-title":"Luteinizing Hormone-Releasing Hormone Antagonists","volume":"19","author":"Manea","year":"2009","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_84","unstructured":"Therapeutic Goods Administration (2024, December 27). Australian Public Assessment\u00a0Report for Degarelix, Available online: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-firmagon.pdf."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejps.2003.08.001","article-title":"The Dosing Solution Influence on the Pharmacokinetics of Degarelix, a New GnRH Antagonist, after s.c. Administration to Beagle Dogs","volume":"20","author":"Koechling","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/OTT.S32426","article-title":"An Update on the Use of Degarelix in the Treatment of Advanced Hormone-Dependent Prostate Cancer","volume":"6","author":"Rick","year":"2013","journal-title":"Onco Targets Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2020.11.008","article-title":"Clinically Established Biodegradable Long Acting Injectables: An Industry Perspective","volume":"167","author":"Nkanga","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0015-0282(99)00414-8","article-title":"Pharmacokinetic and Pharmacodynamic Characteristics of Ganirelix (Antagon\/Orgalutran). Part II. Dose-Proportionality and Gonadotropin Suppression after Multiple Doses of Ganirelix in Healthy Female Volunteers","volume":"72","author":"Mannaerts","year":"1999","journal-title":"Fertil. Steril."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/00003495-200464060-00001","article-title":"Gonadotropin-Releasing Hormone Antagonists for Assisted Reproductive Techniques","volume":"64","author":"Griesinger","year":"2004","journal-title":"Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0015-0282(99)00524-5","article-title":"Prospective, Randomized, Controlled Study of in Vitro Fertilization-Embryo Transfer with a Single Dose of a Luteinizing Hormone-Releasing Hormone (LH-RH) Antagonist (Cetrorelix) or a Depot Formula of an LH-RH Agonist (Triptorelin)","volume":"73","author":"Olivennes","year":"2000","journal-title":"Fertil. Steril."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.18231\/j.jchm.2023.030","article-title":"Role of Cetrorelix in the Prevention and Treatment of Ovarian Hyperstimulation Syndrome: A Prospective Case Control Study","volume":"10","author":"Inani","year":"2024","journal-title":"J. Community Health Manag."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.18203\/2320-1770.ijrcog20233289","article-title":"Role of Cetrorelix in the Prevention and Treatment of Ovarian Hyperstimulation Syndrome: A Prospective Case Control Study","volume":"12","author":"Mishra","year":"2023","journal-title":"Int. J. Reprod. Contracept. Obstet. Gynecol."},{"key":"ref_93","first-page":"62","article-title":"Cetrorelix in Reproductive Medicine","volume":"4","author":"Findeklee","year":"2023","journal-title":"F S Rep."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Al-Inany, H.G. (2011). Gonadotrophin-Releasing Hormone Antagonists for Assisted Reproductive Technology. Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd.","DOI":"10.1002\/14651858.CD001750.pub3"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Aboulghar, M., and Rizk, B. (2022). Role of GnRH Antagonist in Assisted Reproduction. Ovarian Stimulation, Cambridge University Press.","DOI":"10.1017\/9781316477021"},{"key":"ref_96","first-page":"56","article-title":"Ganirelix and the Prevention of Premature Luteinizing Hormone Surges","volume":"4","author":"Mannaerts","year":"2023","journal-title":"F S Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/01443615.2022.2036955","article-title":"Efficacy and Safety of Newly Developed Ganirelix Acetate in Infertile Women for Assisted Reproductive Technology: A Prospective, Randomised, Controlled Study","volume":"42","author":"Han","year":"2022","journal-title":"J. Obstet. Gynaecol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.fertnstert.2023.08.357","article-title":"Oral Gnrh Antagonist Shr7280 for the Prevention of Premature Luteinizing Hormone (LH) Surge in Women Undergoing Controlled Ovarian Hyperstimulation (COH) in Assisted Reproductive Technology (ART)","volume":"120","author":"Chi","year":"2023","journal-title":"Fertil. Steril."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Xu, H., Zhao, S., Gao, X., Wu, X., Xia, L., Zhang, D., Li, J., Zhang, A., and Xu, B. (2021). GnRH Antagonist Protocol with Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.758896"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Wang, L., Wang, N., Yan, Z., Huang, Z., and Fu, C. (2023). Peptide and Peptide-Based Drugs. Privileged Scaffolds in Drug Discovery, Elsevier.","DOI":"10.1016\/B978-0-443-18611-0.00015-2"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1016\/j.fpurol.2023.11.004","article-title":"Comment Je Prescris Le R\u00e9lugolix, Un Nouvel Antagoniste de La LHRH","volume":"34","author":"Boissier","year":"2024","journal-title":"Progr\u00e8s en Urologie-FMC"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1758835921998586","DOI":"10.1177\/1758835921998586","article-title":"Relugolix: A Novel Androgen Deprivation Therapy for Management of Patients with Advanced Prostate Cancer","volume":"13","author":"Saad","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_103","first-page":"317","article-title":"Degarelix for the Treatment of Advanced Prostate Cancer Compared with GnRh-Agonists: A Systematic Review and Meta-Analysis","volume":"30","author":"Hosseini","year":"2016","journal-title":"Med. J. Islam. Repub. Iran."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40265-014-0211-y","article-title":"Degarelix: A Review of Its Use in Patients with Prostate Cancer","volume":"74","author":"Carter","year":"2014","journal-title":"Drugs"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40273-016-0481-1","article-title":"Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","volume":"35","author":"Uttley","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2125.2010.03730.x","article-title":"Degarelix, a Novel GnRH Antagonist, Causes Minimal Histamine Release Compared with Cetrorelix, Abarelix and Ganirelix in an Ex Vivo Model of Human Skin Samples","volume":"70","author":"Koechling","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/humrep\/13.9.2411","article-title":"The Use of a GnRH Antagonist (Cetrorelix) in a Single Dose Protocol in IVF-Embryo Transfer: A Dose Finding Study of 3 versus 2 Mg","volume":"13","author":"Olivennes","year":"1998","journal-title":"Hum. Reprod."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1472-6483(11)60392-1","article-title":"Five Years\u2019 Clinical Use of GnRH Antagonists: Evaluation of Safety and Allergic Potential","volume":"10","author":"Engel","year":"2005","journal-title":"Reprod. Biomed. Online"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jaccao.2023.05.011","article-title":"Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer","volume":"5","author":"Nelson","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.6004\/jnccn.2022.7083","article-title":"Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk","volume":"21","author":"Dragomir","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JCO.2022.40.28_suppl.238","article-title":"Bone Mineral Density Testing and the Risk of Fractures in Men Initiating Androgen-Deprivation Therapy: Population-Based Study","volume":"40","author":"Hu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_112","first-page":"51","article-title":"Effect of Different Schemes of Androgen Deprivation Therapy on Bone Mass Density in Prostate Cancer Patients","volume":"160","year":"2023","journal-title":"Med. Cl\u00ednica"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/36\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:57:52Z","timestamp":1760115472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ph18010036"],"URL":"https:\/\/doi.org\/10.3390\/ph18010036","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}